Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of Epidermal Growth Factor Receptor inhibitors (EGFRi) in molecularly unselected GEA patients have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.
Back from the brink: EGFR inhibition in gastroesophageal cancer
Pinato, David J;
2021-01-01
Abstract
Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of Epidermal Growth Factor Receptor inhibitors (EGFRi) in molecularly unselected GEA patients have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
